ReviewPharmaceutics2021
Recent Advances in Photodynamic Therapy against Fungal Keratitis.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Photodynamic therapy with infracyanine green induces keratocyte depopulation in the normal equine cornea.Equine veterinary journal · 2026Article
- What We Can Do in Infectious Keratitis, Except for Conventional Antimicrobial-Based Therapies: Major Narrative Review.Health science reports · 2026Article
- Bridging Gaps in Fungal Keratitis Management: Novel Diagnostics, Drug Delivery Systems, and Gene Therapies.AAPS PharmSciTech · 2026Review
- Isoimperatorin alleviates fungal keratitis by regulating NF-κB pathway and macrophage immune response.Frontiers in immunology · 2026Article
- Comprehensive insights into the role of nanocarriers in advancing azole-based ocular therapeutics.RSC advances · 2025Review
- Culture positivity of anterior chamber exudate in cases of fungal keratitis.International ophthalmology · 2025Article
- Rose Bengal-Assisted Photodynamic Antimicrobial Therapy for Keratitis.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2025Article
- Photodynamic therapy could serve as a promising approach to prevent posterior capsular opacification.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2025Review
- Idiopathic Fusarium Sclerouveitis: A Case Report.Cornea · 2025Article
- Photodynamic antimicrobial therapy with Erythrosin B, Eosin Y, and Rose Bengal for the inhibition of fungal keratitis isolates: An in vitro study.Journal of photochemistry and photobiology. B, Biology · 2025Article
- Exploring the potential of photodynamic therapy in overcoming multidrug resistance: mechanisms, synergies, and clinical advancements in infectious diseases.Frontiers in cellular and infection microbiology · 2025Review
- Nanomedicine in fungal keratitis: current applications and future prospects.Frontiers in microbiology · 2025Review
- Toxicological Assessment of 2-Hydroxychalcone-Mediated Photodynamic Therapy: Comparative In Vitro and In Vivo Approaches.Pharmaceutics · 2024Article
- Antifungal efficacy of photodynamic therapy on Cryptococcus and Candida species is enhanced by Streptomyces spp. extracts in vitro.Lasers in medical science · 2024Article
- Applications of photodynamic therapy in keratitis.International ophthalmology · 2024Review
- An Overview of Biofilm-Associated Infections and the Role of Phytochemicals and Nanomaterials in Their Control and Prevention.Pharmaceutics · 2024Review
- Recent Advances in Diagnosis and Treatment Approaches in Fungal Keratitis: A Narrative Review.Microorganisms · 2024Review
- Antimicrobial Resistance: Is There a 'Light' at the End of the Tunnel?Antibiotics (Basel, Switzerland) · 2023Review
- Article
- Drug Delivery in Photodynamic Therapy.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Fungal keratitis is a serious clinical infection on the cornea caused by fungi and is one of the leading causes of blindness in Asian countries. The treatment options are currently limited to a few antifungal agents. With the increasing incidence of drug-resistant infections, many patients fail to respond to antibiotics. Riboflavin-mediated corneal crosslinking (similar to photodynamic therapy (PDT)) for corneal ectasia was approved in the US in the early 2000s. Current evidence suggests that PDT could have the potential to inhibit fungal biofilm formation and overcome drug resistance by using riboflavin and rose bengal as photosensitizers. However, only a few clinical trials have been initiated in anti-fungal keratitis PDT treatment. Moreover, the removal of the corneal epithelium and repeated application of riboflavin and rose bengal are required to improve drug penetration before and during PDT. Thus, an improvement in trans-corneal drug delivery is mandatory for a successful and efficient treatment. In this article, we review the studies published to date using PDT against fungal keratitis and aim to enhance the understanding and awareness of this research area. The potential of modifying photosensitizers using nanotechnology to improve the efficacy of PDT on fungal keratitis is also briefly reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.